trending Market Intelligence /marketintelligence/en/news-insights/trending/sOllNknuUscQzJ8wFG7GEg2 content esgSubNav
In This List

Deciphera raises $400M via common stock offering to fund clinical trials

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Deciphera raises $400M via common stock offering to fund clinical trials

Deciphera Pharmaceuticals Inc. raised $400 million through a previously announced underwritten public offering of common shares.

The Waltham, Mass.-based biopharmaceutical company sold 10,810,810 common shares at $37 apiece. The underwriters have a 30-day option to buy up to 1,621,621 additional common shares.

The net proceeds from the offering will be used to fund clinical trials for the company's cancer drugs; ripretinib, rebastinib and DCC-3014. Funds will also be used to develop experimental drugs, for research activities and working capital purposes.

J.P. Morgan, Piper Jaffray and Jefferies were the joint book-running managers for the offering. Guggenheim Securities was the lead manager for the offering, while SunTrust Robinson Humphrey was the co-manager for the offering.